(Q39362619)

11 September 2017

title

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib (English)

1 reference

11 September 2017

main subject

hepatocellular carcinoma

1 reference

5

Bruno Chauffert

0 references

author name string

Zakaria Ezzoukhry

1

1 reference

11 September 2017

Christophe Louandre

2

1 reference

11 September 2017

Eric Trécherel

3

1 reference

11 September 2017

Corinne Godin

4

1 reference

11 September 2017

Sébastien Dupont

6

1 reference

11 September 2017

Momar Diouf

7

1 reference

11 September 2017

Jean-Claude Barbare

8

1 reference

11 September 2017

Jean-Claude Mazière

9

1 reference

11 September 2017

Antoine Galmiche

10

1 reference

11 September 2017

language of work or name

English

0 references

publication date

30 April 2012

1 reference

International Journal of Cancer

11 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

11 September 2017

volume

131

1 reference

11 September 2017

issue

12

1 reference

11 September 2017

page(s)

2961-2969

1 reference

11 September 2017

cites work

Hepatocellular carcinoma

1 reference

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Selection of patients with hepatocellular carcinoma for sorafenib

21 January 2018

1 reference

The RAF proteins take centre stage

21 January 2018

1 reference

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

21 January 2018

1 reference

Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis

21 January 2018

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

Characterization of cell lines established from human hepatocellular carcinoma

21 January 2018

1 reference

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma

21 January 2018

1 reference

The EGF receptor family: spearheading a merger of signaling and therapeutics

21 January 2018

1 reference

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells.

21 January 2018

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

21 January 2018

1 reference

Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma

21 January 2018

1 reference

Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

21 January 2018

1 reference

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics

21 January 2018

1 reference

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.27604

1 reference

11 September 2017

1 reference